From: Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times?
 | Secondary infection (n = 33) | No secondary infection (n = 33) | p value |
---|---|---|---|
Sex | |||
 Male, n (%) | 26 (79%) | 23 (70%) | 0.57 |
 Female, n (%) | 7 (21%) | 10 (30%) | |
Age, years | 67 [60–73] | 65 [56–70] | 0.17 |
BMI, kg/m2 | 27.6 [25.4–31.1] | 27.7 [24.3–30.7] | 0.40 |
APACHE II | 15 [13–19] | 15 [10–19] | 0.77 |
Days between COVID-19 symptoms and hospital admission | 7 [4–10] | 7 [5–11] | 0.72 |
Days between COVID-19 symptoms and ICU admission | 10 [7–13] | 10 [6–14] | 0.96 |
Day of secondary infection (relative to hospital admission) | 16 [13–22] | NA |  |
Day of secondary infection (relative to ICU admission) | 14 [9–21] | NA |  |
Medical history, n (%) | |||
 Cardiovascular insufficiency | 9 (27%) | 9 (27%) | 1.00 |
 Hypertension | 17 (52%) | 16 (48%) | 1.00 |
 Respiratory insufficiency | 2 (6%) | 3 (9%) | 1.00 |
 Renal insufficiency | 0 (0%) | 1 (3%) | 1.00 |
 Metastatic neoplasm | 2 (6%) | 3 (9%) | 1.00 |
 Immunological insufficiency | 0 (0%) | 1 (3%) | 1.00 |
 COPD | 3 (9%) | 3 (9%) | 1.00 |
 Diabetes | 11 (33%) | 4 (12%) | 0.08 |
 Hematologic malignancy | 0 (0%) | 1 (3%) | 1.00 |